From 1 September 2025, access to KALYDECO (ivacaftor) has been expanded under the Pharmaceutical Benefits Scheme (PBS), making this life-changing treatment available to patients aged one month and older who carry at least one gating mutation in the CFTR gene, as well as those with at least one non-gating mutation shown to be responsive to ivacaftor through clinical and/or in vitro data. This expansion marks an important step forward in improving treatment options and quality of life for people living with cystic fibrosis. #CysticFibrosis #Kalydeco #PBS #AccessToMedicine #CFCommunity #HealthUpdates (fb)

Be Part of Groundbreaking CF Research – Share Your Gut Health Story Even with life-changing treatments like Trikafta/Kaftrio, many people with cystic fibrosis still struggle with gut symptoms that remain poorly understood. Why do these issues affect some and not others? A global study is working to uncover the answers, and your experience could make all the difference. By joining, you’ll help researchers: - Understand the hidden side of CF - Improve digestive health care for the whole community - Move closer to personalised treatments for every individual Who can take part? - Adults with CF - Young people aged 6–15 (with parental consent) - Participants worldwide, with or without gut symptoms, on or off modulators Participation is safe, secure, and fully remote. All it takes is downloading the app and sharing your lived experience from home. Your story has the power to shape the future of CF care. Join the study today: 👉 https://www.grampus-cf.org/joinonline #CysticFibrosis #CFGutHealthStudy #CFResearch #DigestiveHealth #PersonalisedCare #HealthInnovation #Trikafta #Kaftrio #LivedExperience (fb)